Cargando…

The role of NAFLD in cardiometabolic disease: an update

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitli...

Descripción completa

Detalles Bibliográficos
Autores principales: Faasse, Sarah, Braun, Hayley, Vos, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811670/
https://www.ncbi.nlm.nih.gov/pubmed/29497497
http://dx.doi.org/10.12688/f1000research.12028.1
_version_ 1783299908662460416
author Faasse, Sarah
Braun, Hayley
Vos, Miriam
author_facet Faasse, Sarah
Braun, Hayley
Vos, Miriam
author_sort Faasse, Sarah
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitlist registrants with non-alcoholic steatohepatitis–induced cirrhosis increased by 170% from 2004 to 2013. In addition, patients with NAFLD are at increased risk of both cardiovascular disease and type II diabetes. In this update, recent studies contributing to the understanding of the place of NAFLD in cardiometabolic disease will be discussed.
format Online
Article
Text
id pubmed-5811670
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-58116702018-02-28 The role of NAFLD in cardiometabolic disease: an update Faasse, Sarah Braun, Hayley Vos, Miriam F1000Res Review Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitlist registrants with non-alcoholic steatohepatitis–induced cirrhosis increased by 170% from 2004 to 2013. In addition, patients with NAFLD are at increased risk of both cardiovascular disease and type II diabetes. In this update, recent studies contributing to the understanding of the place of NAFLD in cardiometabolic disease will be discussed. F1000 Research Limited 2018-02-09 /pmc/articles/PMC5811670/ /pubmed/29497497 http://dx.doi.org/10.12688/f1000research.12028.1 Text en Copyright: © 2018 Faasse S et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Faasse, Sarah
Braun, Hayley
Vos, Miriam
The role of NAFLD in cardiometabolic disease: an update
title The role of NAFLD in cardiometabolic disease: an update
title_full The role of NAFLD in cardiometabolic disease: an update
title_fullStr The role of NAFLD in cardiometabolic disease: an update
title_full_unstemmed The role of NAFLD in cardiometabolic disease: an update
title_short The role of NAFLD in cardiometabolic disease: an update
title_sort role of nafld in cardiometabolic disease: an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811670/
https://www.ncbi.nlm.nih.gov/pubmed/29497497
http://dx.doi.org/10.12688/f1000research.12028.1
work_keys_str_mv AT faassesarah theroleofnafldincardiometabolicdiseaseanupdate
AT braunhayley theroleofnafldincardiometabolicdiseaseanupdate
AT vosmiriam theroleofnafldincardiometabolicdiseaseanupdate
AT faassesarah roleofnafldincardiometabolicdiseaseanupdate
AT braunhayley roleofnafldincardiometabolicdiseaseanupdate
AT vosmiriam roleofnafldincardiometabolicdiseaseanupdate